Literature DB >> 1966931

Anti-neutrophil cytoplasm antibodies in patients with monoclonal gammopathies.

V L Esnault1, D R Jayne, M T Keogan, A A Brownlee, A Testa, D Lecarrer, D L Brown, C M Lockwood.   

Abstract

Anti-neutrophil cytoplasm antibodies (ANCA) are specific markers for systemic vasculitis. In view of the autoreactivity to other autoantigens reported in patients with monoclonal immunoglobulins (MIg), the reactivity of 150 sera from 125 patients with MIg was tested for ANCA by radioimmunoassay (RIA) with inhibition stage and indirect immunofluorescence (IIF). Seven were positive for IgG ANCA, all with IgG MIg and 5 were positive for IgM ANCA, 4 with IgM MIg and 1 with IgG MIg. No IgA ANCA were found. The patterns seen on IIF were identical to those seen with sera from patients with systemic vasculitis and were cytoplasmic in 6 and peri-nuclear in 6. The restriction of the ANCA activity to the MIg was studied in six sera by light chain specific RIA, and anion exchange fractionation of the sera. The ANCA activity appeared to be polyclonal in at least three sera and could be found in the monoclonal fraction in only three patients. Associated autoimmune diseases were found in some of these ANCA positive patients including Sjögren's syndrome, MacDuffie hypocomplementemic vasculitis and rheumatoid polyarthritis but the classical vasculitic features normally associated with ANCA were not observed. We conclude that ANCA is a further autoreactivity present in some sera with MIg and discuss the relation between monoclonal gammopathies and autoimmunity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1966931

Source DB:  PubMed          Journal:  J Clin Lab Immunol        ISSN: 0141-2760


  9 in total

Review 1.  ANCA testing. New developments and clinical implications.

Authors:  A E Ahmed; J B Peter; Y Y Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 2.  ANCA in diseases other than systemic vasculitis.

Authors:  H H Peter; D Metzger; A Rump; E Röther
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

3.  Possible intrinsic association of anti-neutrophil cytoplasmic antibody-associated vasculitis coexisting with multiple myeloma.

Authors:  Huifang Liu; Jiachuan Xiong; Jun Zhang; Ying Zhang; Ling Nie; Yiqin Wang; Jinghong Zhao
Journal:  Oncol Lett       Date:  2016-07-13       Impact factor: 2.967

Review 4.  ANCA and associated diseases: immunodiagnostic and pathogenetic aspects.

Authors:  W L Gross; W H Schmitt; E Csernok
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

5.  Prevalence of antineutrophil cytoplasmic antibody positivity in patients with Hodgkin's and non-Hodgkin lymphoma: a single center experience.

Authors:  Timucin Cil; Abdullah Altintas; Abdurrahman Isikdogan; Sabri Batun
Journal:  Int J Hematol       Date:  2009-05-27       Impact factor: 2.490

6.  Some patients with anti-myeloperoxidase autoantibodies have a C-ANCA pattern.

Authors:  M Segelmark; B Baslund; J Wieslander
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

7.  A Case Report of Multiple Myeloma Associated With Myeloperoxidase and Proteinase-3 Antibodies Posing a Diagnostic Dilemma.

Authors:  Jordana Cheta; Michael Binder
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec

8.  Dual anti-neutrophil cytoplasmic antibody and anti-glomerular basement membrane antibody-positive crescent glomerulonephritis in a patient with monoclonal gammopathy of undetermined significance: A case report.

Authors:  Xiaoli Li; Yunfei Hao; Rong Xue; Xueting Qi; Zhigang Ma
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

9.  Tubulointerstitial nephritis in antineutrophil cytoplasmic antibody-associated vasculitis with monoclonal gammopathy.

Authors:  Erika Hishida; Takahisa Kobayashi; Yuko Ono; Kentaro Oka; Takahiro Masuda; Yoshihiko Ueda; Tetsu Akimoto; Osamu Saito; Daisuke Nagata
Journal:  CEN Case Rep       Date:  2021-07-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.